Core Viewpoint - The animal health sector experienced a decline of 0.85% on October 16, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.1%, while the Shenzhen Component Index fell by 0.25 [1]. Group 1: Market Performance - The closing price of *ST Lvkang was 27.48, with an increase of 5.01%, while other stocks in the sector showed mixed results [1]. - The total trading volume for the animal health sector was significant, with *ST Lvkang recording a volume of 14,900 hands and a transaction amount of 40.81 million yuan [1]. - The overall market saw a net outflow of 126 million yuan from the animal health sector, with retail investors contributing a net inflow of 91.62 million yuan [2]. Group 2: Individual Stock Analysis - *ST Lvkang had a net inflow of 5.23 million yuan from major funds, while Xianfeng Holdings saw a net outflow of 3.36 million yuan [3]. - The stock of RuiPu Bio had a significant net outflow of 25.44 million yuan from major funds, despite a retail net inflow of 39.62 million yuan [3]. - The stock of HaiLi Bio experienced a net outflow of 4.47 million yuan from major funds, with a retail net inflow of 2.64 million yuan [3].

证券代码：300119 证券简称：瑞普生物 公告编号：2025-083 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 2025 年第五次临时股东大会决议公告 1、本次股东大会无变更、否决议案的情况； 2、本次股东大会以现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 瑞普生物股份有限公司（以下简称"公司"）2025年9月30日以董事会公告方式 向全体股东发出召开2025年第五次临时股东大会的通知。（公告编号：2025-077）。 本次股东大会采取现场投票、网络投票相结合的方式召开。其中现场会议于2025 年10月15日下午14:30在公司会议室召开，公司董事长李守军先生因工作原因缺席， 根据《公司法》第一百一十四条及《公司章程》第六十八条的规定，经公司过半数 董事同意，推选公司董事、总经理徐雷先生主持本次会议；通过深圳证券交易所系 统进行网络投票的时间为2025年10月15日09:15-09:25，09:30-11:30，13:00-15:00； 通过深圳证券交易所互联网系统投票的具体时间为2025年10月15日09:15-15:00 ...

中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于瑞普生物股份有限公司 2025 年第五次临时股东大会的法律意见书 致：瑞普生物股份有限公司 受瑞普生物股份有限公司（以下简称"公司"）聘请，北京市通商律师事务 所指派律师（以下简称"本所律师"）出席了公司 2025 年第五次临时股东大会 （以下简称"本次股东大会"），并依据《中华人民共和国公司法》（以下简称 "《公司法》"）、《上市公司股东会规则》、《深圳证券交易所上市公司股东 会网络投票实施细则》等法律、法规、规章、规范性文件及《瑞普生物股份有限 公司章程》（以下简称"《公司章程》"）的规定，对公司本次股东大会召集及 召开 ...

Core Insights - The animal health sector experienced a 1.5% increase on October 15, with Bio-Pharmaceuticals leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Bio-Pharmaceuticals (600201) closed at 11.03, up 4.06% with a trading volume of 563,500 shares and a turnover of 614 million yuan [1] - Other notable stocks include: - Shunlian Bio (688098) at 10.48, up 2.95% [1] - Ruipu Bio (300119) at 22.56, up 2.31% [1] - Yongshun Bio (920729) at 676, up 1.93% [1] - Dayu Bio (920970) at 9.45, up 1.61% [1] Capital Flow - The animal health sector saw a net outflow of 5.71 million yuan from institutional investors, while retail investors contributed a net inflow of 1.83 million yuan [2] - The capital flow for key stocks includes: - Ruipu Bio had a net inflow of 25.55 million yuan from institutional investors [3] - Hai Li Bio experienced a net outflow of 3.22 million yuan from institutional investors [3] - KQ Bio (688526) had a net inflow of 5.26 million yuan from retail investors [3]

Core Viewpoint - Reap Bio plans to establish a partnership to invest in the pet industry chain, enhancing its competitive edge through collaboration with specialized institutions [1] Group 1: Investment Strategy - Reap Bio aims to expand its layout in the pet industry chain as part of its strategic planning [1] - The company will collaborate with Tianjin Port Free Trade Zone Emerging Industry Development Fund, Tianjin Lingang Equity Investment Fund Management, and Mingzhi Hexin (Tianjin) Equity Investment Fund Management to form a new investment partnership [1] - The total subscribed capital of the partnership is set at RMB 406 million, with Reap Bio contributing RMB 154 million, representing 37.93% of the total [1]

Core Viewpoint - Reap Bio plans to establish a partnership to invest in the pet industry chain, enhancing its competitive edge through collaboration with specialized institutions [1] Group 1: Investment Strategy - Reap Bio aims to expand its layout in the pet industry chain by forming a partnership with Tianjin Port Free Trade Zone Emerging Industry Development Fund, Tianjin Lingang Equity Investment Fund Management, and Mingzhi Hexin (Tianjin) Equity Investment Fund Management [1] - The total subscribed capital for the partnership is set at RMB 406 million, with Reap Bio contributing RMB 154 million, representing 37.9310% of the total [1]

Group 1 - The company, Reap Bio (300119.SZ), announced its intention to invest in the establishment of Tianjin Baorui Equity Investment Partnership (Limited Partnership) for the purpose of investing in the pet industry chain [1] - The total committed capital for the partnership is 406 million yuan, with the company contributing 154 million yuan from its own funds as a limited partner [1]

Core Viewpoint - The company, Reap Bio (300119.SZ), plans to invest in the pet industry by establishing a partnership fund with a total commitment of 406 million yuan, contributing 154 million yuan from its own funds [1] Group 1 - The company is participating in the establishment of Tianjin Baorui Equity Investment Partnership (Limited Partnership) [1] - The total subscribed capital of the partnership is 406 million yuan [1] - The company will act as a limited partner, investing 154 million yuan of its own funds [1]

Group 1 - The core point of the article is that Reap Bio (SZ 300119) held a temporary board meeting on October 13, 2025, to discuss investment proposals with professional investment institutions [1] - For the year 2024, Reap Bio's revenue composition is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chains, and 2.38% from other sources [1] - As of the report date, Reap Bio has a market capitalization of 10.2 billion yuan [1]

第五届监事会第二十四次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届监事会第二十四次（临 时）会议于 2025 年 10 月 13 日在公司会议室以现场表决方式召开。会议通知于 2025 年 10 月 6 日以书面及电子邮件等方式送达全体监事。公司应出席监事 3 人， 实际出席监事 3 人，参与表决监事 3 人。本次会议由监事会主席周仲华先生主持。 本次会议的召集、召开和表决程序符合《公司法》《证券法》等法律法规和《公 司章程》的规定。 证券代码：300119 证券简称：瑞普生物 公告编号：2025-081 瑞普生物股份有限公司 二、监事会会议审议情况 1、审议通过了《关于与专业投资机构共同投资的议案》 经与会监事签字并加盖公司印章的监事会决议。 特此公告。 瑞普生物股份有限公司监事会 二〇二五年十月十四日 1 经审议，监事会认为公司本次与专业机构共同投资事项符合《深圳证券交易 所创业板股票上市规则》及《深圳证券交易所上市公司自律监管指引第7号—— 交易与关联交易》等 ...